echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Blood System > ATMP Europe recommended approval of five drugs at its November meeting

    ATMP Europe recommended approval of five drugs at its November meeting

    • Last Update: 2020-11-25
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    At its November meeting, the European Medicines Agency's Human Medicines Committee (CHMP) recommended approval of five drugs for market.
    CHMP recommends that Phesgo (pertuzumab/trastuzumab) be used to treat early and metastasis HER2-positive breast cancer patients.
    Phesgo is a fixed dose combination of HER djubial inhibitors Pertuzumab and HER2 monoantigen Herceptin (trastuzumab) and hyalurase, injected under the skin.
    photo source: Roclanda (latanoprost/netarsudil) eye drops are recommended to reduce elevated in-eye pressure (IOP) in primary open-angle glazing or high-eye pressure adult patients.
    photo source: Baloxavir marboxil is recommended for the treatment of simple influenza aged 12 and over.
    also recommends that Roche's oral antiviral drug be approved to prevent influenza in people 12 years of age and older.
    Photo Source: It is recommended that anti-VEGF monoantigen Onbevzi (Roche Beva monoantigen) be used to treat colorectal cancer, breast cancer, non-small cell lung cancer, renal cell carcinoma, ovarian epithelial cancer, fallopian tubes, primary peritronal cancer and cervical cancer.
    photo source: CHMP recommends using tagraxofusp, a cytotoxin targeted at CD123, for the treatment of bullet-like plasma cell-like dendroid cytoblastoma (BPDCN).
    picture source:
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.